NCT06941129View on ClinicalTrials.gov

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases

PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 11, 2025

Primary Completion Date

February 18, 2028

Study Completion Date

March 18, 2028

Conditions
Systemic Lupus ErythematosusSystemic Sclerosis (SSc)Inflammatory MyopathyANCA-Associated Vasculitis (AAV)Connective Tissue Disease-Associated ThrombocytopeniaSLE-ITP
Interventions
BIOLOGICAL

UCAR T-cell

universal allogeneic anti-CD19/BCMA CAR T-cells

Trial Locations (1)

Unknown

RECRUITING

Institute of Hematology & Blood Diseases Hospital, Tianjin

All Listed Sponsors
collaborator

Shanghai Xiniao Biotech Co., Ltd.

INDUSTRY

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER